Impact of adjuvant trastuzumab on locoregional failure rates in a randomized clinical trial: North Central Cancer Treatment Group N9831 (alliance) study.

ABSTRACT:

Background

The goal of this study was to assess the impact of trastuzumab on locoregional failure.

Methods

The analysis included 2763 patients with HER2-positive (HER2+) breast cancer who were randomly assigned to adjuvant doxorubicin (A), cyclophosphamide (C), paclitaxel (T) and trastuzumab (H) (arm A, AC→T [n = 922]; arm B, AC→T→H [n = 988]; arm C, AC→T+H→H [n = 853]). Radiotherapy was given after AC→T concurrently with H. Radiotherapy was given after lumpectomy (L) or after mastectomy (M) with ≥4 positive lymph nodes but was optional for 1 to 3 positive lymph nodes. Locoregional failures at 10 years (LFR10) as first events were compared using competing risk analysis.

Results

The median follow-up was 13.0 years. The first site of failure was local-only in 96 cases,

SUBMITTER: Vargas CE 

PROVIDER: S-EPMC7686244 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature